This is real life

Real-world studies now prove the efficacy (exacerbation and OCS reduction compared to baseline) of Nucala in everyday practice.¹ ²

This page contains real world evidence. This is a real patient with eosinophilic asthma, compensated by GSK for his time.

Nucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older.³ The page contains real world evidence. This is a fictional patient for illustrative purposes.

Nucala is the only anti-IL-5 to demonstrate long-term reduction in exacerbations and OCS dose for up to 4.8 years.²,

REALITI-A real-world study

REALITI-A is an interim analysis of the early initiators with 12 months of data.

Nucala Nucala

Ratio rate: 0.31 CI:0.27-0.35 p<0.001
Baseline | 4.63 (over previous 12 months)
At 12 months | 1.43 with Nucala

Nucala Nucala

95% CI: 50-75
Baseline | 10mg
At 12 months | 5mg

† 52% is the median percent reduction from baseline in average daily dose of maintenance OCS.
Results are descriptive. Statistical significance not achieved. Study limitations: These data are a prespecified interim analysis of 368 patients who completed 12 months of follow-up as of Feb 2019. This analysis may not reflect the results from the final dataset.

COSMEX long term study

Offer your patients sustained reduction in OCS dose
Nucala Nucala

Baseline | 11.3 mg/day
Week 128 | with Nucala 1.3 mg/day

COSMEX (4.8 year study) 88% reduction in OCS dose vs. baseline at 2.5 years. Results are descriptive. Statistical significance not achieved.
In total, 95 patients with ≥188 weeks of continuous reporting across MENSA, COSMOS and COSMEX with ≤12 weeks between the last dose in COSMOS and first dose in COSMEX are summarised (MENSA: placebo [n=24], Nucala [n=71]). The Nucala group in MENSA contains patients on both 100mg SC and 75mg IV doses (75mg IV dose is not an approved dose of Nucala). Analyses include clinically significant exacerbations from MENSA and all exacerbations from COSMOS and COSMEX.

Nucala: Mechanism of action

Video player requires JavaScript enabled. You can download this video here:

Nucala: The power to choose at home or in clinic administration³

Nucala offers at-home administration that lets appropriate patients self-administer without the need to come into the clinic or hospital. Nucala is the only 4 weekly asthma biologic with a simple fixed dose.³

The recommended dose of Nucala is 100mg SC once every 4 weeks in adults and adolescents 12 years and older, available in a pre-filled pen, prefilled syringe or lyophilised powder. The licensed dose of Nucala in children aged 6–11 years is 40mg SC once every 4 weeks, regardless of weight, and available in lyophilised powder.

Identify and support patients with severe eosinophilic asthma

Identifying Patient

Identify patients with elevated eosinophil levels that are eligible for Nucala

Patient Support Material

Support for you and your patients when starting treatment with Nucala


*Defined as deterioration in asthma requiring use of systemic corticosteroids and/or an ED visit and/or hospital admission.

Real-world studies are designed to evaluate associations among variables and not to definitively establish causality. These limitations are important when interpreting results: lack of comparator arm, differences in patient populations and data collection vs. randomised controlled trials.5 France ATU (cohort of patients in France) was a retrospective observational study.¹

Nucala is generally well tolerated. In clinical trials, Nucala had a similar incidence of adverse events vs placebo with the exception of injection site reactions (8% vs. 3% respectively, n-385), which occurred mainly within the first three injections.³

The long-term safety and immunogenicity profile of Nucala was similar to that observed in placebo-controlled asthma trials.4

ATU, Authorised for Temporary Use; CI, confidence interval; ED, emergency department; IV, intravenous; OCS, oral corticosteroid; SC, subcutaneous.


  1. Taillé C et al. Eur Respir J 2020; in press (
  2. GlaxoSmithKline data on file. REALITI-A CSR. REF-74585
  3. Nucala SmPC, 2020
  4. Khurana S et al. Clin Ther 2019; 41:2041-2056
  5. Leather DA, et al. Adv Ther. 2020;1-21

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441

© 2021 GSK group of companies or its licensor.
Trade marks are owned by or licensed to the GSK group of companies.

PM-GB-MPL-WCNT-200040 v2 | January 2021